Randomised clinical trial: Psychological intervention improves work productivity and daily activity by reducing abdominal pain and fatigue in Crohn's disease. Issue 8 (2nd February 2023)

• Record Type: Journal Article
• Authors: Regev, Shirley; Schwartz, Doron; Sarid, Orly; Goren, Ganit; Slonim‐Nevo, Vered; Friger, Michael; Sergienko, Ruslan; Greenberg, Dan; Monsonego, Alon; Nemirovsky, Anna; Odes, Shmuel
• Is Part Of: Alimentary pharmacology & therapeutics. Volume 57:Issue 8(2023)
• Page Start: 861
• Page End: 871
• Publication Date: 2023-02-02
• Subjects: abdominal pain -- disability -- fatigue -- inflammatory bowel disease -- mediation analysis -- randomised controlled trial; Digestive organs -- Diseases -- Treatment -- Periodicals; Digestive organs -- Effect of drugs on -- Periodicals; Gastrointestinal system -- Diseases -- Treatment -- Periodicals; Gastrointestinal system -- Effect of drugs on -- Periodicals; 615.73
• DOI: 10.1111/apt.17399
• Languages: English
• ISSNs: 0269-2813

Abstract

Summary: Background: Chronic abdominal pain and fatigue are characteristics of Crohn's disease (CD) and contribute to functional impairments. Aims: To examine whether CD‐tailored cognitive‐behavioural and mindfulness intervention (COBMINDEX) is effective in reducing abdominal pain and fatigue in patients with CD and whether changes in abdominal pain and fatigue mediate any beneficial effects of COBMINDEX on impairments in work productivity and daily activities. Methods: This is a secondary analysis of a parallel‐group multicentre randomised controlled trial. Patients with mild‐to‐moderate CD ( n = 142) were randomised into either intervention group receiving COBMINDEX, or control group receiving treatment‐as‐usual for 3 months followed by COBMINDEX. Complete data were collected from 120 patients (34.0 ± 10.7 years, 62.5% female, intervention = 60, control = 60). Analysis of covariance assessed group differences in 3‐month follow‐up scores, controlling for baseline scores. Multiple parallel mediation analysis assessed the proposed mechanisms for the entire sample. Results: The intervention group demonstrated significantly lower levels of abdominal pain ( F = 17.46, p < 0.001, η 2 p = 0.13), fatigue ( F = 7.26, p = 0.008, η 2 p = 0.06) and impairments at work ( F = 4.82, p = 0.032, η 2 p = 0.07) and daily activities ( F = 6.26, p = 0.014, η 2 p = 0.05), compared with treatment‐as‐usual. Moreover, changes in abdominal pain and fatigue significantly mediated the beneficial effects of COBMINDEX on patients' work productivity ( b = −9.90, SE = 2.86, 95% CI: −16.11 to −4.94) and daily activities ( b = −9.65, SE = 1.91, 95% CI: −13.77 to 6.35), independent of changes in disease activity. Conclusions: COBMINDEX is effective at reducing abdominal pain and fatigue in patients with CD, which in turn leads to improvement in functioning. Clinicians should incorporate screening for severe abdominal pain and fatigue and consider offering cognitive‐behavioural and mindfulness training. ClinicalTrials.gov, Number: NCT05085925. Ministry of Health in Israel (https://my.health.gov.il/CliniTrials/Pages/MOH_2020‐02‐24_008721.aspx ). Abstract :